Albumin paclitaxel/neutrophil drug
PreclinicalBiologic
Albumin paclitaxel/neutrophil drug is one of 23 biologic programs targeting Breast Cancer. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
22
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
2828 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Halaven
EisaiPreclinical
Cymbalta
Alnylam PharmaceuticalsPreclinical
MS Contin
Merck & Co.Preclinical
Zinecard
CChildren's Oncology Group
Preclinical
Spravato
WWim Janssens
Preclinical
Effexor
WWyeth-Lederle Vaccines
Preclinical
Chirocaine
PPurdue Pharma LP
Preclinical
Nubain
AAultman Health Foundation
Preclinical
Aquasol E
NNational Eye Institute (NEI)
Preclinical
Vfend
PPrism Pharmaceuticals
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Preclinical[1]
- Company
- JJIANG LONGWEI